Logo
x

Search

Subscribe Now

Sobi

Sobi Reports the US FDA’s sNDA Acceptance of Doptelet (Avatrombopag) to Treat Pediatric Immune Thrombocytopenia

Sobi Reports the US FDA’s sNDA Acceptance of Doptelet (Avatrombopag) to Treat Pediatric Immune Thrombocytopenia

  • December 13, 2024
Sobi’s Altuvoct Receives the EC’s Marketing Authorization to Treat Haemophilia A

Sobi’s Altuvoct Receives the EC’s Marketing Authorization to Treat Haemophilia A

  • June 19, 2024
Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A

Sobi Reports EMA’s Validation of MAA for Efanesoctocog Alfa to Treat Haemophilia A

  • May 19, 2023
Sobi to Acquire CTI BioPharma for ~$1.7B

Sobi to Acquire CTI BioPharma for ~$1.7B

  • May 11, 2023
PharmaShots' Key Highlights of First Quarter 2023

PharmaShots' Key Highlights of First Quarter 2023

  • April 3, 2023
Sobi and ADC Therapeutics Zynlonta (loncastuximab tesirine) Receives EC’s Conditional Marketing Authorisation for Diffuse Large B-Cell Lymphoma

Sobi and ADC Therapeutics Zynlonta (loncastuximab tesirine) Receives EC’s Conditional Marketing Authorisation for Diffuse Large B-...

  • December 21, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.